NEW YORK (360Dx) – SeLux Diagnostics is developing an antimicrobial susceptibility (AST) platform that it anticipates will meet clinicians' requirements allowing them to quickly prescribe the correct antibiotics to patients.

The AST system, using a microplate-compatible bacterial surface area assay and standard microbiology lab technology, is expected to provide results within the first day following a sample culture to enable clinicians to accordingly prescribe the most suitable antibiotic for their patients' medical conditions, the firm said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.